1. AB0803 EFFICACY OF TILDRAKIZUMAB IN PsA: DAS28-CRP SCORES THROUGH WEEK 52. (2nd June 2020) Authors: Chohan, S.; Kavanaugh, A.; Strand, V.; Chou, R. C.; Mendelsohn, A. M.; Rozzo, S.; Mease, P. J. Journal: Annals of the rheumatic diseases Issue: Volume 79(2020)Supplement 1 Page Start: 1702 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. OP0230 EFFICACY AND SAFETY OF TILDRAKIZUMAB, A HIGH-AFFINITY ANTI–INTERLEUKIN-23P19 MONOCLONAL ANTIBODY, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS IN A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE-DOSE, PHASE 2B STUDY. (2nd June 2020) Authors: Mease, P. J.; Chohan, S.; García Fructuoso, F. J.; Gottlieb, A. B.; Luggen, M. E.; Rahman, P.; Raychaudhuri, S. P.; Chou, R. C.; Mendelsohn, A. M.; Rozzo, S.; Orbai, A. M. Journal: Annals of the rheumatic diseases Issue: Volume 79(2020)Supplement 1 Page Start: 145 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Port wine stain treatment outcomes have not improved over the past three decades. (23rd April 2019) Authors: van Raath, M.I.; Chohan, S.; Wolkerstorfer, A.; van der Horst, C.M.A.M.; Storm, G.; Heger, M. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 33:Number 7(2019) Page Start: 1369 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗